Aurobindo gets USFDA nod for Sumatriptan Succinate tablets
August 12, 2009 – 10:05 am | 31 views
|
Aurobindo Pharma, a leading drug manufacturing company today received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sumatriptan Succinate tablets drug in strengths of 25 mg and 50 mg and 100 mg.
The tablets are indicated for the treatment of acute migraine headaches and falls under the central nervous system (CNS) therapeutic segment. The product has been shipped for commercial launch.
Sumatriptan Succinate tablets 25 mg and 50 mg and 100 mg are the generic equivalent of GlaxoSmithKline Imitrex tablets 25 mg and 50 mg and 100 mg.
Aurobindo Pharma has a total of 100 ANDA approvals (72 final approvals and 28 tentative approvals) from USFDA.
Tags: ANDA, Aurobindo, Aurobindo Pharma, CNS, GlaxoSmithKline, pharma, Sumatriptan Succinate, US Food & Drug, US Food & Drug Administration, USFDA
